Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes

Robert J. Chilton, Kathleen M. Dungan, Jay H. Shubrook, Guillermo E. Umpierrez

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Cardiovascular disease (CVD) is the primary cause of morbidity and mortality in patients with type 2 diabetes (T2D). This review examines the impact of cardiovascular outcome trials (CVOTs) on clinical practice. To date, all CVOTs have shown non-inferiority versus placebo (both added to standard of care) against a primary endpoint of 3- or 4-point major adverse cardiovascular event (MACE), confirming CV safety of these treatments. Additionally, some CVOTs have shown superiority to placebo against the same MACE endpoint, suggesting a cardioprotective action for these treatments. This is reflected in guideline updates, which primary care physicians should consider when personalizing treatments.

Original languageEnglish (US)
Pages (from-to)193-212
Number of pages20
JournalPrimary Care Diabetes
Volume14
Issue number3
DOIs
StatePublished - Jun 2020

Keywords

  • Antihyperglycemic
  • Cardiovascular outcome trials
  • Cardiovascular risk
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Fingerprint Dive into the research topics of 'Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes'. Together they form a unique fingerprint.

Cite this